[
  {
    "ts": null,
    "headline": "Will Danaher (DHR) Beat Estimates Again in Its Next Earnings Report?",
    "summary": "Danaher (DHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
    "url": "https://finnhub.io/api/news?id=5efee5a6da3dfe062e1fe1e4d8211bb6ecaa901667595411e9b5bdfa248fc891",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735924213,
      "headline": "Will Danaher (DHR) Beat Estimates Again in Its Next Earnings Report?",
      "id": 132262357,
      "image": "https://media.zenfs.com/en/zacks.com/7853de8d69faeccb7d1ad6ebba40b8a2",
      "related": "DHR",
      "source": "Yahoo",
      "summary": "Danaher (DHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
      "url": "https://finnhub.io/api/news?id=5efee5a6da3dfe062e1fe1e4d8211bb6ecaa901667595411e9b5bdfa248fc891"
    }
  },
  {
    "ts": null,
    "headline": "Danaher price target lowered to $268 from $278 at Evercore ISI",
    "summary": "Evercore ISI lowered the firm’s price target on Danaher (DHR) to $268 from $278 and keeps an Outperform rating on the shares. In the firm’s 2025 outlook note for MedTech, Life Science Tools and Diagnostics, the analyst argues that FY25 guides from the life science tools group are likely to be conservative on China and Pharma, while in MedTech the firm contends that “healthy” utilization trends and a margin expansion thesis support the group. Published first on TheFly – the ultimate source for re",
    "url": "https://finnhub.io/api/news?id=fdc6444f42ba013177a4fca7ffdaf6e76c3a75e5b738e2c4170155160ef06e34",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735904799,
      "headline": "Danaher price target lowered to $268 from $278 at Evercore ISI",
      "id": 132255054,
      "image": "https://media.zenfs.com/en/tipranks_452/052dd4274c5cf5d2329a934917618434",
      "related": "DHR",
      "source": "Yahoo",
      "summary": "Evercore ISI lowered the firm’s price target on Danaher (DHR) to $268 from $278 and keeps an Outperform rating on the shares. In the firm’s 2025 outlook note for MedTech, Life Science Tools and Diagnostics, the analyst argues that FY25 guides from the life science tools group are likely to be conservative on China and Pharma, while in MedTech the firm contends that “healthy” utilization trends and a margin expansion thesis support the group. Published first on TheFly – the ultimate source for re",
      "url": "https://finnhub.io/api/news?id=fdc6444f42ba013177a4fca7ffdaf6e76c3a75e5b738e2c4170155160ef06e34"
    }
  }
]